DaubeerUP, great reminder post, but kind of wish you did not remind me of December 2014. I was approaching $100,000 net value with my IPIX holding and lots in ADXS. Hmmm, no Christmas presents on those. Maybe a lots better value in December 2019. I can hope, yes?
Leo claiming successful trials is subject to debate. How much was spent on 2 Absssi trials? Where did that success lead the company? Why was the last K trial needed when it was obvious "oral delivery" was the correct route? If P phase 2B is such a success, why is the data such a mystery? Claiming 100 percent trial perfection is ludicrous.